Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Wednesday, September 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2023 Cantor Global Healthcare Conference, scheduled for September 26, 2023. Members of the management team will join a fireside chat to discuss the company's focus on developing novel drug candidates for immuno-inflammatory diseases. A webcast of the event will be available on Aclaris' website and archived for 30 days. This engagement highlights Aclaris' commitment to addressing patient needs in this therapeutic area.
Price reaction · baseline $7.4 (2023-09-19 close) · hit after-hours · clean, no other ACRS news in the window
day 0 close
-8.5%
day 1
-7.8%
day 3 · peak
-11.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris Therapeutics is actively engaging in important industry events.
  • The company is focused on novel drug candidates for unmet medical needs.
  • The fireside chat offers an opportunity to share insights about their pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:

Frequently Asked Questions

When is Aclaris Therapeutics' fireside chat scheduled?

The fireside chat is set for September 26, 2023, at 10:30 AM ET.

How can I access the Aclaris fireside chat webcast?

You can access the webcast via the Events page on Aclaris' website.

What diseases does Aclaris Therapeutics focus on?

Aclaris Therapeutics develops treatments for immuno-inflammatory diseases.

Is the webcast of the fireside chat available for later viewing?

Yes, the webcast will be archived for at least 30 days on their website.

What type of company is Aclaris Therapeutics, Inc.?

Aclaris is a clinical-stage biopharmaceutical company focused on drug development.

ShareAdd on Google
Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics Cantor Global Healthcare immuno-inflammatory diseases biopharmaceutical company
Last updated: Sep 20, 2023

Biotech snapshot

Cash runway
$171M liquidity · $7M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ATI-045Phase 2
Atopic Dermatitis →

Catalyst track record

+181%
best trade around ACRS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACRS.

See every catalyst's timing & PoA →